The commercial launch of Placebell©™ for peripheral neuropathic pain in October 2017 has increased interest from biopharma industry stakeholders in T4P’s low-risk validated technology. This escalation in interest has led Tools4Patient to build a seasoned business development team with extensive clinical scientific expertise. The T4P team is now focused on making Placebell©™ broadly available to sponsors facing difficulties in managing the placebo response in clinical trials. The Placebell©™ technology has previously been validated in two clinical studies that demonstrated a 30% reduction in treatment response variance in patients administered placebo.
Erica Smith, PhD joined Tools4Patient as VP, Business Development with a strong scientific background in pharmaceutical drug development at Wyeth Research and Pfizer. Dr. Smith has worked in business leadership positions at multiple CROs including Lovelace Biomedical, CBSET, Inc. and Charles River Laboratories. Tom Pillsworth, PhD joined Tools4Patient as an Executive Consultant with more than 30 years of experience in both pharmaceutical companies and CROs, leading operations and business development. Dr. Pillsworth’s positions included leadership roles at Phoenix International Life Sciences, Inveresk Research, PharmaNet and Quartesian. In addition, Dr. Pillsworth has been an adjunct professor in biological sciences and chemistry / biochemistry at California State University, San Marcos.
T4P is excited to introduce Placebell©™ to companies ranging from big pharma, biotech, generics and medical device sponsors with the expectation that this technology will significantly shorten clinical development timelines, reduce cost and increase